LataMed AI Updates on Forward Stock Split and AI Platform Progress

LataMed AI Corp. (OTC: LMED) has provided shareholders with an update on its 5-for-1 forward stock split and mandatory share exchange process. As of July 7, 2026, the company submitted all requested information to FINRA, and management anticipates the corporate action may become effective within approximately the next week, pending FINRA's review. The forward stock split will be implemented with a new CUSIP number 21116R404, replacing the current CUSIP upon effectiveness. The company detailed the process for different types of shareholders: those holding shares through brokerage accounts or in book-entry form generally need not take any action, as the exchange will be processed automatically. Physical stock certificate holders are not required to surrender their certificates immediately, but when they do submit them for transfer, sale, or exchange, the certificates will be processed under the new CUSIP. Dr. Kevin Rodan Levy, CEO, emphasized the company's focus on advancing its telemedicine platform and pursuing licensing opportunities for its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms. He believes the forward stock split supports corporate development and strategic initiatives while facilitating the new capital structure. The company encourages shareholders with questions to contact their brokerage or transfer agent. LataMed AI Corp. is a development-stage digital health and AI technology company focused on building telehealth infrastructure and AI-enabled healthcare solutions for emerging markets, with an initial focus on Latin America. The company's strategy includes developing technology platforms for healthcare access, patient engagement, provider coordination, and data-driven operations. This update was originally distributed via NEWMEDIAWIRE.

The forward stock split and mandatory share exchange are key corporate actions that will adjust the number of outstanding shares and update the company's CUSIP. FINRA's approval is the final step before the split becomes effective. The company's management has provided detailed guidance to ensure shareholders understand the process, particularly for those holding physical certificates. The new CUSIP number 21116R404 will be assigned to the post-split shares, facilitating trading and identification. LataMed AI Corp. (OTC: LMED) is publicly traded on the OTC markets, and the forward split is intended to support its continued corporate development and strategic initiatives, including the expansion of its AI platforms. The company's CEO highlighted that the split will allow management to focus on advancing the telemedicine platform and pursuing commercialization opportunities for CardioAI, PulmoAI, and NeuroAI, which are designed to enhance healthcare delivery in Latin America.

LataMed AI Corp. operates in the digital health space, aiming to build an integrated digital healthcare ecosystem. The forward stock split is a structural change that does not alter the company's fundamental business but is designed to improve the capital structure and potentially attract a broader investor base. The company's AI platforms target cardiovascular, pulmonary, and neurological conditions, reflecting a focus on high-impact disease areas. As a development-stage company, LataMed is working to deploy its technology in emerging markets where healthcare access is limited. The successful implementation of the stock split and the advancement of its AI platforms are critical milestones for the company's growth strategy. Shareholders are advised to monitor updates from FINRA and the company's transfer agent for the official effective date and further instructions.